{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:10:40Z","timestamp":1787015440243,"version":"build-2736575974"},"reference-count":43,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The majority of patients with psoriasis vulgaris (chronic plaque psoriasis) can be treated successfully with short\u2010term topical therapies. However, long\u2010term management of psoriasis with topicals is challenging and tends to take a reactive approach to disease relapse, rather than a proactive approach aimed at maintaining disease remission. Patients are often dissatisfied with the delay in treatment response and inconvenience of applying topical treatments, and therefore frequently discontinue treatment leading to poor outcomes. Relapse is common, particularly with reactive management, as underlying residual disease can remain following initial skin clearance; some patients find that their disease at relapse may be worse than their initial symptoms. This can have a detrimental effect on patient quality of life (QoL) and increase the risk of psoriasis\u2010associated depression. A long\u2010term proactive management approach, with maintenance treatment following initial treatment success, could help sustain disease remission and improve clinical and QoL outcomes for patients. Treatment with fixed\u2010dose calcipotriol 50\u00a0\u00b5g\/g betamethasone dipropionate 0.5\u00a0mg\/g cutaneous foam (Cal\/BD foam) is effective in the short term, providing a fast onset of action and improvements in disease at 4\u00a0weeks. Results from the Phase III PSO\u2010LONG study demonstrated that long\u2010term proactive management was superior to reactive management in prolonging time to first relapse, reducing number of relapses and increasing days in remission in adults with psoriasis vulgaris. Furthermore, Cal\/BD foam was well tolerated in PSO\u2010LONG. No new safety concerns were identified over 52\u00a0weeks; the safety profile was consistent with that described previously. Given this, Cal\/BD foam should be considered when prescribing topicals for the long\u2010term proactive management for patients with psoriasis.<\/jats:p>","DOI":"10.1111\/jdv.17053","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T03:02:48Z","timestamp":1614049368000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Addressing challenges associated with long\u2010term topical treatment and benefits of proactive management in patients with psoriasis"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"M.","family":"Lebwohl","sequence":"first","affiliation":[{"name":"Department of Dermatology Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine University of L\u00fcbeck L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"626","article-title":"Psoriasis","volume":"87","author":"Weigle N","year":"2013","journal-title":"Am Fam Physician"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03389.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033217"},{"issue":"2","key":"e_1_2_9_5_1","first-page":"S36","article-title":"Topical therapies for psoriasis: improving management strategies and patient adherence","volume":"35","author":"Stein Gold LF","year":"2016","journal-title":"Semin Cutan Med Surg"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1729335"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_2_9_8_1","first-page":"36","article-title":"Innovation that drives your dermatological future","volume":"5","author":"Bonnekoh B","year":"2017","journal-title":"EMJ Dermatol"},{"key":"e_1_2_9_9_1","unstructured":"EMC.Enstilar Cutaneous Foam \u2010 Summary of Product Characteristics;2019. URLhttps:\/\/www.medicines.org.uk\/emc\/medicine\/31833(last accessed: 4 June 2020)."},{"key":"e_1_2_9_10_1","unstructured":"FDA.Enstilar \u2010 Prescribing Information;2019. URLhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/207589s005s006s007lbl.pdf(last accessed: 4 June 2020)."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.037"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.4065\/76.9.943"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.209622"},{"key":"e_1_2_9_14_1","unstructured":"InformedHealth.org [Internet].Cologne Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006\u2010. Topical treatments for psoriasis;2017. URLhttps:\/\/www.ncbi.nlm.nih.gov\/books\/NBK435705\/(last accessed: 8 June 2020)."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2012.07919.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1201189"},{"key":"e_1_2_9_17_1","first-page":"519","article-title":"Topical therapies for psoriasis: evidence\u2010based review","volume":"51","author":"Afifi T","year":"2005","journal-title":"Can Fam Physician"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.12.021"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)80057-7"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12276"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000018283"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(87)80553-4"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5965.255-a"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-35"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.280"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93396"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302313"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.11.033"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-019-00766-z"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.5455\/msm.2014.26.168-171"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.39.10.767"},{"key":"e_1_2_9_33_1","first-page":"181","article-title":"Alcohol as a risk factor for plaque\u2010type psoriasis","volume":"76","author":"Behnam SM","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23681.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04570.x"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/571912"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03829.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2005.05.022"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/104973202129119874"},{"key":"e_1_2_9_40_1","first-page":"167","article-title":"A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ\u20105D\u2010derived utility values","volume":"6","author":"M\u00f8ller AH","year":"2015","journal-title":"Patient Relat Outcome Meas"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2013.02.009"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10280.x"},{"key":"e_1_2_9_43_1","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3227031643","article-title":"Impact of psoriasis flare and remission on quality of life and work productivity: a real\u2010world study in the USA","volume":"22","author":"Korman NJ","year":"2016","journal-title":"Dermatol Online J"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/247553031700200306"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17053","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17053","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T16:22:28Z","timestamp":1693585348000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":43,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/jdv.17053"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17053","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"2020-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}